專利授權區國立清華大學國際產學營運總中心 Operations Center for Industry Collaboration

搜尋專利授權區

關鍵字

» 新增關鍵字

選單

專利授權區

專利授權區
專利名稱(中)	抑制COVID-19病毒的組合和製藥用途
專利名稱(英)	COMBINATION AND USE FOR MANUFACTURING MEDICAMENT FOR THE SUPPRESSION OF COVID-19 VIRUS
專利家族	中華民國：202333673(公開號) 美國：12,370,236
專利權人	國立清華大學 50.00% ,普睿思股份有限公司 40.00% ,國立臺灣大學 10.00%
發明人	楊立威,蔡昆霖,黃邦杰,鄭伊芸,張淑媛
技術領域	生化醫藥,資訊工程

專利摘要(中)
本揭露提供一種藉由阻斷SARS-CoV2的類3C主蛋白酶(3C-like main protease，3CLpro)之二聚體形成以於有其需要的個體中治療SARS-CoV2 3CLpro相關疾病之方法，包含投予該個體第一藥劑，其與SARS-CoV2 3CLpro複合體之第一結合位點結合，以及投予該個體第二藥劑，其與SARS-CoV2 3CLpro複合體之第二結合位點結合；其中，該第一結合位點和該第二結合位點於SARS-CoV2 3CLpro複合體之3D結構中為功能上相異的位點。本揭露亦提供一種藥物組合，其包含該第一藥劑及該第二藥劑以抑制SARS-CoV2，從而減緩COVID-19。

專利摘要(中)

本揭露提供一種藉由阻斷SARS-CoV2的類3C主蛋白酶(3C-like main protease，3CLpro)之二聚體形成以於有其需要的個體中治療SARS-CoV2 3CLpro相關疾病之方法，包含投予該個體第一藥劑，其與SARS-CoV2 3CLpro複合體之第一結合位點結合，以及投予該個體第二藥劑，其與SARS-CoV2 3CLpro複合體之第二結合位點結合；其中，該第一結合位點和該第二結合位點於SARS-CoV2 3CLpro複合體之3D結構中為功能上相異的位點。本揭露亦提供一種藥物組合，其包含該第一藥劑及該第二藥劑以抑制SARS-CoV2，從而減緩COVID-19。

專利摘要(英)
Provided is a method for treating a SARS-CoV2 3CLpro-related disease in a subject in need thereof by blocking dimerization of 3C-like main protease (3CLpro) of the SARS-CoV2, including administering to the subject a first agent which binds to a first binding site of a SARS-CoV2 3CLpro complex and a second agent which binds to a second binding site of the SARS-CoV2 3CLpro complex, wherein the first binding site and the second binding site are functionally different sites in the three-dimensional structure of the SARS-CoV2 3CLpro complex. Also provided is a pharmaceutical combination including the first agent and the second agent for suppressing SARS-CoV2, thereby alleviating COVID-19.

專利摘要(英)

Provided is a method for treating a SARS-CoV2 3CLpro-related disease in a subject in need thereof by blocking dimerization of 3C-like main protease (3CLpro) of the SARS-CoV2, including administering to the subject a first agent which binds to a first binding site of a SARS-CoV2 3CLpro complex and a second agent which binds to a second binding site of the SARS-CoV2 3CLpro complex, wherein the first binding site and the second binding site are functionally different sites in the three-dimensional structure of the SARS-CoV2 3CLpro complex. Also provided is a pharmaceutical combination including the first agent and the second agent for suppressing SARS-CoV2, thereby alleviating COVID-19.

聯絡資訊
承辦人姓名	黃允恬
承辦人電話	(03)571-5131#62305
承辦人Email	yuntian@mx.nthu.edu.tw